Shane Lloyd
( out of 82 reviews )

Shane Lloyd, MD

Languages spoken: English

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Hospital South

Radiation Oncology
1950 Circle of Hope
Salt Lake City , UT 84112
801-581-2396
Get Directions

Sugar House Health Center

1280 E. Stringham Avenue
Salt Lake City , UT 84106
801-581-2000
Get Directions

  • Shane Lloyd, MD, is an associate professor of radiation oncology at the University of Utah School of Medicine and Huntsman Cancer Institute. Dr. Lloyd is passionate about providing the best possible care for patients with gastrointestinal, head and neck, and genitourinary cancers.

    Dr. Lloyd is originally from Utah. He received his MD and MHS degrees from Yale University School of Medicine. He completed an internship at the University of Utah, and a residency in radiation oncology at Yale New Haven Hospital in New Haven, Connecticut.

    Dr. Lloyd believes in demonstrating and improving care quality through data collection and analysis. He strives to make the best clinical trials available to his patients. Dr. Lloyd has authored numerous peer-reviewed research manuscripts about cancer treatment. He serves as the chair of the Radiological Drug Research Committee (RDRC) and Human Use Subcommittee of the Radiation Safety Committee (HUS-RSC).

    Specialties

    Board Certification

    American Board of Radiology (Radiation Oncology)

    Patient Rating

    5.0 /5
    ( out of 82 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    HUNTSMAN CANCER CENTER

    Every staff member seems to have the patients best interests at heart and love their job

    HUNTSMAN CANCER CENTER

    Good

    HUNTSMAN CANCER CENTER

    not only a good doctor but is a good person

    HUNTSMAN CANCER CENTER

    Dr. Lloyd always listens carefully to all my concerns. He discusses options with me and helps me to get the care that I need. Dr. Lloyd is the best!

    HUNTSMAN CANCER CENTER

    Phenomenal doctor. Takes all the time in the world answering questions and never in a rush. Always feel confident that I have received the best care possible.

    HUNTSMAN CANCER CENTER

    Very positive. Dr. Lloyd put me at ease with explanation of care and including me in decision making.

    HUNTSMAN CANCER CENTER

    Dr Lloyd is an outstanding physician who provides excellent care. I am fortunate to be his patient.

    HUNTSMAN CANCER CENTER

    They have my highest recommendation. l

    HUNTSMAN CANCER CENTER

    I don't make financial or medical recommendations.

  • Shane Lloyd, MD, is an associate professor of radiation oncology at the University of Utah School of Medicine and Huntsman Cancer Institute. Dr. Lloyd is passionate about providing the best possible care for patients with gastrointestinal, head and neck, and genitourinary cancers.

    Dr. Lloyd is originally from Utah. He received his MD and MHS degrees from Yale University School of Medicine. He completed an internship at the University of Utah, and a residency in radiation oncology at Yale New Haven Hospital in New Haven, Connecticut.

    Dr. Lloyd believes in demonstrating and improving care quality through data collection and analysis. He strives to make the best clinical trials available to his patients. Dr. Lloyd has authored numerous peer-reviewed research manuscripts about cancer treatment. He serves as the chair of the Radiological Drug Research Committee (RDRC) and Human Use Subcommittee of the Radiation Safety Committee (HUS-RSC).

    Board Certification and Academic Information

    Academic Departments Radiation Oncology -Associate Professor
    Board Certification
    American Board of Radiology (Radiation Oncology)

    Education history

    Undergraduate Economics and Zoology - Brigham Young University B.A.
    Graduate Training Yale School of Medicine M.H.S.
    Professional Medical Medicine - Yale School of Medicine M.D.
    Research Fellow Yale School of Medicine Research Fellow
    Internship Internal Medicine - University of Utah Affiliated Hospitals Intern
    Residency Radiation Oncology - Yale-New Haven Hospital Resident

    Selected Publications

    Journal Article

    1. Lloyd S, Yu JB, Wilson LD, Decker RH (2011). Determinants and patterns of survival in adenoid cystic carcinoma of the head and neck, including an analysis of adjuvant radiation therapy. Am J Clin Oncol, 34(1), 76-81. (Read full publication)
    2. Lloyd S, Yu JB, Wilson LD, Judson BL, Decker RH (2012). The prognostic importance of midline involvement in oral tongue cancer. Am J Clin Oncol, 35(5), 468-73. (Read full publication)
    3. Lloyd S, Dosoretz AP, Yu JB, Evans SB, Decker RH (2016). Academic and Resident Radiation Oncologists' Attitudes and Intentions Regarding Radiation Therapy near the End of Life. Am J Clin Oncol, 39(1), 85-9. (Read full publication)
    4. McLaughlin PW, Liss AL, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, Movsas B, Prestidge BR, Showalter TN, Taira AV, Vapiwala N, Davis BJ (2017). ACR Appropriateness Criteria(R) Locally Advanced, High-Risk Prostate Cancer. Am J Clin Oncol, 40(1), 1-10. (Read full publication)
    5. Gustafson GS, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Hsu IC, Lloyd S, Mclaughlin PW, Merrick GS, Showalter TN, Taira AV, Vapiwala N, Yamada Y, Davis B (2014). ACR appropriateness Criteria(R) Postradical prostatectomy irradiation in prostate cancer. Oncology (Williston Park, N.Y.), 28(12), 1125-30, 1132-6. (Read full publication)
    6. Yu JB, Lloyd S, Decker RH, Wilson LD, Park H (2012). Comparative Effectiveness Research and the Surveillance, Epidemiology, and End Results database: what is Comparative Effectiveness Research (CER) and why is it important?. Current problems in cancer, 36(4), 208-15. (Read full publication)
    7. Park HS, Lloyd S, Decker RH, Wilson LD, Yu J (2012). Overview of the Surveillance, Epidemiology, and End Results database: evolution, data variables, and quality assurance. Current problems in cancer, 36(4), 183-90. (Read full publication)
    8. Lloyd S, Park HS, Wilson LD, Decker RH, Yu J (2012). Prediction models, nomograms, and staging validation with the Surveillance, Epidemiology, and End Results database: using Surveillance, Epidemiology and End Results (SEER) program to create prediction models. Current problems in cancer, 36(4), 200-7. (Read full publication)
    9. Park HS, Lloyd S, Decker RH, Wilson LD, Yu J (2012). Limitations and biases of the Surveillance, Epidemiology, and End Results database. Current problems in cancer, 36(4), 216-24. (Read full publication)
    10. Lloyd S, Park HS, Decker RH, Wilson LD, Yu J (2012). Using the Surveillance, Epidemiology, and End Results database to investigate rare cancers, second malignancies, and trends in epidemiology, treatment, and outcomes. Current problems in cancer, 36(4), 191-9. (Read full publication)
    11. Cannon RB, Sowder JC, Buchmann LO, Hunt JP, Hitchcock YJ, Lloyd S, Grossman KF, Monroe M (2017). Increasing use of nonsurgical therapy in advanced-stage oral cavity cancer: A population-based study. Head & neck, 39(1), 82-91. (Read full publication)
    12. Sowder JC, Cannon RB, Buchmann LO, Hunt JP, Hitchcock Y, Lloyd S, Grossmann KF, Monroe M (2017). Treatment-related determinants of survival in early-stage (T1-2N0M0) oral cavity cancer: A population-based study. Head & neck, 39(5), 876-880. (Read full publication)
    13. Cannon RB, Kull AJ, Carpenter PS, Francis S, Buchmann LO, Monroe MM, Lloyd S, Hitchcock YJ, Cannon D, Weis JR, Houlton JJ, Hunt J (2019). Adjuvant radiation for positive margins in adult head and neck sarcomas is associated with improved survival: Analysis of the National Cancer Database. Head & neck, 41(6), 1873-1879. (Read full publication)
    14. Lloyd S, Yu JB, Ross DA, Wilson LD, Decker R (2010). A prognostic index for predicting lymph node metastasis in minor salivary gland cancer. International journal of radiation oncology, biology, physics, 76(1), 169-75. (Read full publication)
    15. Moran MS, Ma S, Jagsi R, Yang TJ, Higgins SA, Weidhaas JB, Wilson LD, Lloyd S, Peschel R, Gaudreau B, Rockwell (2013). A prospective, multicenter study of complementary/alternative medicine (CAM) utilization during definitive radiation for breast cancer. International journal of radiation oncology, biology, physics, 85(1), 40-6. (Read full publication)
    16. Lloyd S, Chen Z, Foss FM, Girardi M, Wilson L (2013). Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides. Journal of the American Academy of Dermatology, 69(4), 537-43. (Read full publication)
    17. Aylward A, Abdelaziz S, Hunt JP, Buchmann LO, Cannon RB, Lloyd S, Hitchcock Y, Hashibe M, Monroe M (2019). Rates of Dysphagia-Related Diagnoses in Long-Term Survivors of Head and Neck Cancers. Otolaryngology--head and neck surgery, 161(4), 643-651. (Read full publication)
    18. An Y, Jiang W, Andraos TY, Reddy JP, Yehia ZA, Lloyd S, Duvic M, D'Souza NM, Milgrom SA, Pinnix CC, Oki Y, Smith GL, Wilson LD, Dabaja B (2019). Multi-institutional Investigation: Circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides. Radiotherapy and oncology, 131, 88-92. (Read full publication)
    19. Torrecillas V, Shepherd HM, Francis S, Buchmann LO, Monroe MM, Lloyd S, Cannon D, Hitchcock YJ, Weis JR, Hunt JP, Houlton JJ, Cannon R (2018). Adjuvant radiation for T1-2N1 oral cavity cancer survival outcomes and utilization treatment trends: Analysis of the SEER database. Oral oncology, 85, 1-7. (Read full publication)
    20. Husain ZA, Lloyd S, Shah C, Wilson LD, Koshy M, Mahmood (2015). Changes in brachytherapy-based APBI patient selection immediately before and after publication of the ASTRO consensus statement. Brachytherapy, 14(4), 490-5. (Read full publication)
    21. Orton A, Boothe D, Gan M, Monroe MM, Hitchcock YJ, Lloyd (2016). The "decay" of brachytherapy use in tumors of the oral cavity: A population-based patterns of care and outcomes analysis from 1973 to 2012. Brachytherapy, 15(6), 851-858. (Read full publication)
    22. Odei BC, Boothe D, Lloyd S, Gaffney D (2016). A comprehensive analysis of brachytherapy clinical trials over the past 15 years. Brachytherapy, 15(6), 679-686. (Read full publication)
    23. Davis BJ, Taira AV, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Showalter TN, Vapiwala (2016). ACR appropriateness criteria permanent source brachytherapy for prostate cancer.LID - S1538-4721(16)30558-X [pii]LID - 10.1016/j.brachy.2016.10.002 [doi]. Brachytherapy, (Read full publication)
    24. Lloyd S, Alektiar KM, Nag S, Huang YJ, Deufel CL, Mourtada F, Gaffney D (2017). Intraoperative high-dose-rate brachytherapy: An American Brachytherapy Society consensus report. Brachytherapy, 16(3), 446-465. (Read full publication)
    25. Lloyd S, Buscariollo DL, Gross CP, Makarov DV, Yu J (2013). Determinants of enrollment in cancer clinical trials: the relationship between the current state of knowledge, societal disease burden, and randomized clinical trial enrollment. Journal of the National Comprehensive Cancer Network, 11(8), 928-36. (Read full publication)
    26. Lloyd S, Chang B (2013). A comparison of three treatment strategies for locally advanced and borderline resectable pancreatic cancer. Journal of gastrointestinal oncology, 4(2), 123-30. (Read full publication)
    27. Lloyd S, Chang B (2013). New possibilities and potential benefits for local control in locally recurrent pancreatic cancer. Journal of gastrointestinal oncology, 4(4), 340-2. (Read full publication)
    28. Lloyd S, Chang B (2014). Current strategies in chemoradiation for esophageal cancer. Journal of gastrointestinal oncology, 5(3), 156-65. (Read full publication)
    29. Frandsen J, Boothe D, Gaffney DK, Wilson BD, Lloyd (2015). Increased risk of death due to heart disease after radiotherapy for esophageal cancer. Journal of gastrointestinal oncology, 6(5), 516-23. (Read full publication)
    30. Boothe D, Hopkins Z, Frandsen J, Lloyd (2016). Comparison of external beam radiation and brachytherapy to external beam radiation alone for unresectable extrahepatic cholangiocarcinoma. Journal of gastrointestinal oncology, 7(4), 580-7. (Read full publication)
    31. Tao R, Ager B, Lloyd S, Torgeson A, Denney M, Gaffney D, Kharofa J, Lin SH, Koong AC, Anzai Y, Hoffman J (2018). Hypoxia imaging in upper gastrointestinal tumors and application to radiation therapy. Journal of gastrointestinal oncology, 9(6), 1044-1053. (Read full publication)
    32. Gajiwala S, Torgeson A, Garrido-Laguna I, Kinsey C, Lloyd (2018). Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle. Journal of gastrointestinal oncology, 9(6), 1014-1026. (Read full publication)
    33. Gan M, Boothe D, Neklason DW, Samadder NJ, Frandsen J, Keener MB, Lloyd (2017). Outcomes and complications of radiation therapy in patients with familial adenomatous polyposis. Journal of gastrointestinal oncology, 8(4), 643-649. (Read full publication)
    34. Lloyd S, Decker RH, Evans S (2013). Bone scan findings of chest wall pain syndrome after stereotactic body radiation therapy: implications for the pathophysiology of the syndrome. Journal of thoracic disease, 5(2), E41-4. (Read full publication)
    35. Lloyd S, Chung DH, Colaco RJ, Goodrich I, Cardinale F (2015). The Effect of Dose and Other Parameters on Outcomes in CyberKnife Stereotactic Radiosurgery for Trigeminal Neuralgia. Journal of radiation oncology, 4(4), 387-394.
    36. Coffman A., Boothe D., Frandsen J, Lloyd (2016). Correlates and trends of IMRT use in locally advanced rectal cancer. doi:10.1007/s13566-016-0285-0. Journal of radiation oncology, 5(4), 427-35.
    37. Lloyd S, Decker R (2013). Conference Scene: Notable Trial Results in Radiation Therapy for Lung Cancer at the ASCO Annual Meeting. Lung cancer management, 2(4), 271-4.
    38. Ganesan K, Lloyd S, Sarkar (2016). Discovering Related Clinical Concepts Using Large Amounts of Clinical Notes. Biomedical engineering and computational biology, 7(Suppl 2), 27-33. (Read full publication)
    39. Zaorsky NG, Showalter TN, Ezzell GA, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Taira AV, Vapiwala N, Davis B (2017). ACR Appropriateness Criteria® External Beam Radiation Therapy Treatment Planning for Clinically Localized Prostate Cancer, Part II of II. Advances in radiation oncology, 2(3), 437-54.
    40. Monroe MM, Buchmann LO, Hunt JP, Hitchcock YJ, Lloyd S, Hashibe (2017). The Benefit of Adjuvant Radiation in Surgically-Treated T1-2 N1 Oropharyngeal Squamous Cell Carcinoma. Laryngoscope investigative otolaryngology, 2(2), 57-62. (Read full publication)
    41. Fenlon JB, Hutten RJ, Weil CR, Lloyd S, Cannon DM, Kerrigan K, Cannon RB, Hitchcock Y (2022). Comparing adjuvant radiation to adjuvant chemoradiation in postsurgical p16+ oropharyngeal carcinoma patients with extranodal extension or positive margins. Head & neck, 44(3), 606-614. (Read full publication)
    42. Parsons MW, Hutten RJ, Tward A, Khouri A, Peterson J, Morrell G, Lloyd S, Cannon DM, Johnson S (2022). The Effect of Maximum Tumor Diameter by MRI on Disease Control in Intermediate and High-risk Prostate Cancer Patients Treated With Brachytherapy Boost. Clinical genitourinary cancer, 20(1), e68-e74. (Read full publication)
    43. Hutten RJ, Parsons MW, Weil CR, Tward JD, Lloyd S, Sanchez A, Lester-Coll N, Johnson S (2021). Temporal Trends and Predictors in Diagnosing Pathologic Node-Positive Prostate Cancer in Clinically Node-Negative Patients. Clinical genitourinary cancer, 19(6), e360-e366. (Read full publication)
    44. Odell DW, Albrechtsen RD, Sindt JE, Gole R, Brown S, Parsons MW, Paxton AB, Sarkar V, Lloyd S, Brogan SE, Tao (2021). The Effect of Measured Radiotherapy Dose on Intrathecal Drug Delivery System Function. Neuromodulation, 24(7), 1204-1208. (Read full publication)
    45. Parsons M, Lloyd S, Johnson S, Scaife C, Varghese T, Glasgow R, Garrido-Laguna I, Tao (2021). Refusal of Local Therapy in Esophageal Cancer and Impact on Overall Survival. Annals of surgical oncology, 28(2), 663-675. (Read full publication)
    46. Hutten RJ, Weil CR, Tward JD, Lloyd S, Johnson S (2021). Patterns of Care and Treatment Outcomes in Locoregional Squamous Cell Carcinoma of the Prostate. European urology open science, 23, 30-33. (Read full publication)
    47. Sarkar V, Lloyd S, Paxton A, Dial C, Rassiah P, Szegedi MW, Hitchcock YJ, Salter B (2021). Evaluation of the dosimetric impact of changes in shoulder position on target coverage for spine SBRT to metastases in the lower cervical spine region. Journal of radiosurgery and SBRT, 7(4), 321-328. (Read full publication)
    48. Szegedi M, Boehm C, Paxton A, Rassiah-Szegedi P, Sarkar V, Zhao H, Su F, Kokeny KE, Lloyd S, Tward J, Salter B (2020). Comparison of transperineal ultrasound image guidance technique to transabdominal technique for prostate radiation therapy. Medical physics, 47(12), 6113-6121. (Read full publication)
    49. Tward JD, O'Neil B, Boucher K, Kokeny K, Lowrance WT, Lloyd S, Cannon D, Stephenson RA, Agarwal N, Farr T, Petragallo R, Sherar NZ, Kunz I, Hofer A, Courdy S, Shrieve DC, Dechet (2020). Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy. Clinical genitourinary cancer, 18(4), 274-283.e5. (Read full publication)
    50. Wells SM, Boothe D, Ager BJ, Tao R, Gilcrease GW 3rd, Lloyd (2020). Analysis of Nonsurgical Treatment Options for Metastatic Rectal Cancer. Clinical colorectal cancer, 19(2), 91-99.e1. (Read full publication)
    51. Aylward A, Park J, Abdelaziz S, Hunt JP, Buchmann LO, Cannon RB, Rowe K, Snyder J, Deshmukh V, Newman M, Wan Y, Fraser A, Smith K, Lloyd S, Hitchcock Y, Hashibe M, Monroe M (2020). Individualized prediction of late-onset dysphagia in head and neck cancer survivors. Head & neck, 42(4), 708-718. (Read full publication)
    52. Gruhl JD, Garrido-Laguna I, Francis SR, Affolter K, Tao R, Lloyd (2020). The impact of squamous cell carcinoma histology on outcomes in nonmetastatic pancreatic cancer. Cancer medicine, 9(5), 1703-1711. (Read full publication)
    53. Swords DS, Francis SR, Lloyd S, Garrido-Laguna I, Mulvihill SJ, Gruhl JD, Christensen MC, Stoddard GJ, Firpo MA, Scaife C (2019). Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy. Journal of gastrointestinal surgery, 23(7), 1401-1413. (Read full publication)
    54. Coffman A, Torgeson A, Lloyd (2019). Correlates of Refusal of Surgery in the Treatment of Non-metastatic Pancreatic Adenocarcinoma. Annals of surgical oncology, 26(1), 98-108. (Read full publication)
    55. Sarkar V, Lloyd S, Paxton A, Huang L, Su FC, Tao R, Tward J, Zhao H, Salter (2018). Daily breathing inconsistency in pancreas SBRT: a 4DCT study. Journal of gastrointestinal oncology, 9(6), 989-995. (Read full publication)
    56. Mancini BR, Stein S, Lloyd S, Rutter CE, James E, Chang BW, Lacy J, Johung K (2018). Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer. Journal of gastrointestinal oncology, 9(6), 982-988. (Read full publication)
    57. Orton A, Boothe D, Evans D, Lloyd S, Monroe MM, Jensen R, Shrieve DC, Hitchcock Y (2018). Esthesioneuroblastoma: A Patterns-of-Care and Outcomes Analysis of the National Cancer Database. Neurosurgery, 83(5), 940-947. (Read full publication)
    58. Nevala-Plagemann C, Francis S, Cavalieri C, Tao R, Whisenant J, Glasgow R, Scaife C, Lloyd S, Garrido-Laguna (2018). Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO open, 3(5), e000386. (Read full publication)
    59. Torgeson A, Garrido-Laguna I, Tao R, Cannon GM, Scaife CL, Lloyd (2018). Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins. ESMO open, 3(1), e000282. (Read full publication)
    60. Torgeson A, Lloyd S, Boothe D, Cannon G, Garrido-Laguna I, Whisenant J, Lewis M, Kim R, Scaife C, Tao (2017). Chemoradiation Therapy for Unresected Extrahepatic Cholangiocarcinoma: A Propensity Score-Matched Analysis. Annals of surgical oncology, 24(13), 4001-4008. (Read full publication)
    61. Francis SR, Orton A, Thorpe C, Stoddard G, Lloyd S, Anker C (2017). Toxicity and Outcomes in Patients With and Without Esophageal Stents in Locally Advanced Esophageal Cancer. International journal of radiation oncology, biology, physics, 99(4), 884-894. (Read full publication)
    62. Torgeson A, Lloyd S, Boothe D, Tao R, Whisenant J, Garrido-Laguna I, Cannon G (2017). Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer. Cancer, 123(19), 3816-3824. (Read full publication)
    63. Parsons M, Lloyd S, Johnson S, Scaife C, Soares H, Kim R, Kim R, Garrido-Laguna I, Tao (2022). The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. Journal of gastrointestinal cancer, 54(2), 492-500. (Read full publication)
    64. Hutten RJ, Weil CR, Gaffney DK, Kokeny K, Lloyd S, Rogers CR, Suneja (2022). Worsening Racial Disparities in Utilization of Intensity Modulated Radiation Therapy. Advances in radiation oncology, 7(3), 100887. (Read full publication)
    65. Jairam V, Yu JB, Aneja S, Wilson LD, Lloyd (2017). Differences in Funding Sources of Phase III Oncology Clinical Trials by Treatment Modality and Cancer Type. American journal of clinical oncology, 40(3), 312-317. (Read full publication)
    66. Tao R, Chen Y, Kim S, Ocier K, Lloyd S, Poppe MM, Lee CJ, Glenn MJ, Smith KR, Fraser A, Deshmukh V, Newman MG, Snyder J, Rowe KG, Gaffney DK, Haaland B, Hashibe (2022). Mental health disorders are more common in patients with Hodgkin lymphoma and may negatively impact overall survival. Cancer, 128(19), 3464-3572. (Read full publication)
    67. Rock CB, Hutten RJ, Weil CR, Lloyd S, Kerrigan KC, Cannon RB, Hitchcock Y (2022). Survival outcomes for patients with T3N0M0 squamous cell carcinoma of the glottis treated with definitive radiation alone versus chemoradiation. Head & neck, 45(2), 431-438. (Read full publication)
    68. Hallemeier CL, Moughan J, Haddock MG, Herskovic AM, Minsky BD, Suntharalingam M, Zeitzer KL, Garg MK, Greenwald BD, Komaki RU, Puckett LL, Kim H, Lloyd S, Bush DA, Kim HE, Lad TE, Meyer JE, Okawara GS, Raben A, Schefter TE, Barker JL Jr, Falkson CI, Videtic GMM, Jacob R, Winter KA, Crane C (2023). Association of Radiotherapy Duration With Clinical Outcomes in Patients With Esophageal Cancer Treated in NRG Oncology Trials: A Secondary Analysis of NRG Oncology Randomized Clinical Trials. JAMA network open, 6(4), e238504. (Read full publication)
    69. Hutten R, Khouri A, Parsons M, Tward A, Wilson T, Peterson J, Morrell G, Dechet C, O'Neil B, Schmidt B, Kokeny K, Lloyd S, Cannon D, Tward J, Sanchez A, Johnson (2022). The Clinical Significance of Maximum Tumor Diameter on MRI in Men Undergoing Radical Prostatectomy or Definitive Radiotherapy for Locoregional Prostate Cancer. Clinical genitourinary cancer, 20(6), e453-e459. (Read full publication)
    70. Hutten RJ, Weil CR, Gaffney DK, Kokeny K, Lloyd S, Rogers CR, Suneja (2022). Racial and Ethnic Health Disparities in Delay to Initiation of Intensity-Modulated Radiotherapy. JCO oncology practice, 18(10), e1694-e1703. (Read full publication)
    71. Mao YS, Gao SG, Li Y, Hao AL, Liu JF, Li XF, Rong TH, Fu JH, Ma JQ, Xu MQ, Zhang RQ, Xiao GM, Fu XN, Chen KN, Mao WM, Liu YY, Liu HX, Zhang ZR, Fang Y, Fu DH, Wei XD, Yuan LG, Muhammad S, Wei WQ, Chiu PW, Lloyd S, Schlottmann F, Meredith K, Pimiento JM, Gao YB, He (2022). Efficacy and safety of esophagectomy via left thoracic approach versus via right thoracic approach for middle and lower thoracic esophageal cancer: a multicenter randomized clinical trial (NST1501). Annals of translational medicine, 10(16), 904. (Read full publication)
    72. Huang D, Chang CE, Newman M, Deshmukh V, Snyder J, Date A, Galvao C, Lloyd S, Henry NL, O'Neil B, Hashibe (2023). Adverse health outcomes among rural prostate cancer survivors: A population-based study. Cancer epidemiology, 86, 102430. (Read full publication)
    73. Koric A, Mark B, Chang CP, Lloyd S, Dodson M, Deshmukh VG, Newman M, Date A, Gren LH, Porucznik CA, Haaland B, Henry NL, Hashibe (2023). Adverse Health Outcomes Among Rural And Urban Breast Cancer Survivors: A Population-Based Cohort Study. Cancer epidemiology, biomarkers & prevention, 86(102430), 1302-1311. (Read full publication)
    74. Nielsen S, O'Neil B, Chang CP, Mark B, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Henry NL, Lloyd S, Hashibe (2023). Determining the association of rurality and cardiovascular disease among prostate cancer survivors. Urologic oncology, 41(10), 429.e15-429.e23. (Read full publication)
    75. Price RG, Lloyd S, Wang X, Haaland B, Nelson G, Salter (2023). Adipose Tissue Distribution and Body Mass Index (BMI) Correlation With Daily Image-Guided Radiotherapy (IGRT) Shifts of Abdominal Radiation Therapy Patients. Cureus, 15(6), e40979. (Read full publication)
    76. Hu S, Chang CP, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Haaland B, Porucznik CA, Gren LH, Sanchez A, Lloyd S, O'Neil B, Hashibe (2023). Mental health outcomes in a population-based cohort of patients with prostate cancer. Journal of the National Cancer Institute, 116(3), 445-454. (Read full publication)
    77. Hu S, Chang CP, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Porucznik CA, Gren LH, Sanchez A, Lloyd S, Haaland B, O'Neil B, Hashibe (2023). Comparing Active Surveillance and Watchful Waiting With Radical Treatment Using Machine Learning Models Among Patients With Prostate Cancer. JCO clinical cancer informatics, 7, e2300083. (Read full publication)
    78. Kachnic LA, Winter K, Suntharalingam M, Ilson D, Konski A, Lloyd S, McAvoy SA, Lad T, Olowokure OG, Samson P, Gore EM, Meyer JE, Videtic GMM, Clump DA, Raben A, Kayaleh O, Barker J Jr, Haddock MG, Hopkins JO, Bruner D (2024). Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery. Quality of life research, (Read full publication)
    79. Galarza Fortuna GM, Grass D, Maughan BL, Jain RK, Dechet C, Beck J, Schuetz E, Sanchez A, O'Neil B, Poch M, Li R, Lloyd S, Tward J, Phunrab T, Hawks JL, Swami U, Boucher KM, Agarwal N, Gupta (2025). Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT). Journal for immunotherapy of cancer, 13(3), (Read full publication)
    80. Howell JN, Mark B, Wada DA, Bowling M, Wei M, Lloyd SL, Gaffney DK, Maity A, LaRiviere MJ, Rule WG, Grant JD, Deshmukh V, Newman M, Date A, Hashibe M, Tao (2025). Mental Health Diagnoses in Patients With Mycosis Fungoides and Potential Impact on Oncologic Outcomes. Cancer medicine, 14(5), e70577. (Read full publication)
    81. Tward J, Lloyd S, Johnson S, Dechet C, Nei BO, Maughan B, Swami U, Gupta S, Sanchez A, Kokeny K, Agarwal (2025). A Phase 2 Trial of Radium(223) and Stereotactic Ablative Radiation Therapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone: The RadSABR Study. International journal of radiation oncology, biology, physics, (Read full publication)
    82. Kabarriti R*, Lloyd S* (co-first author), Jabalee J, Del Vecchio Fitz C, Tao R, Slater T, Jacobs C, Inocencio S, Rutenberg M, Matthiesen C, Neff K, Liu GF, Juarez TM, Liauw S (2025). Evaluating Tumor Tissue Modified Viral (TTMV)-HPV DNA for the Early Detection of Anal Squamous Cell Carcinoma Recurrence. Cancers, 17(2), (Read full publication)
    83. Koric A, Chang CE, Lloyd S, Dodson M, Deshmukh VG, Newman MG, Date AP, Doherty JA, Gren LH, Porucznik CA, Haaland BA, Henry NL, Hashibe (2024). Capturing Chemotherapy and Radiotherapy Dose Among Breast Cancer Patients With the Utah All-Payer Claims Database Compared With Gold-Standard Abstraction. Cancer medicine, 13(22), e70411. (Read full publication)
    84. Liu K, Chang CE, Lloyd S, Tao R, Nguyen T, Zhang ZF, Hashibe (2025). The risk of type 2 diabetes among older Asian, Native Hawaiian and Pacific Islander colorectal cancer survivors:a population-based study using SEER-Medicare database. Cancer epidemiology, biomarkers & prevention, (Read full publication)
    85. Feigenberg SJ, Costabile F, Tanes C, Bittinger K, O'Connor R, Agarwal D, Skoufos G, Salaris S, Hatzigeorgiou A, Kostopoulos N, Lloyd S, Friedes C, Chen L, Yegya-Raman N, Cengel K, Levin W, Valenti¿ B, Quarton T, Shestov AA, Berman A, Bradley J, Maity A, Koumenis C, Ben-Josef E, Facciabene (2025). Enhancing outcomes in medically inoperable early-stage NSCLC with gut-targeted antibiotics and stereotactic body radiotherapy: results from a randomized pilot study. Journal for immunotherapy of cancer, 13(7), (Read full publication)
    86. Paccione EN, Kwan E, Bergquist JA, Shah AS, Orkild BA, Hunt B, Salter ML, Mendes J, DiBella E, Arai AE, Bunch TJ, MacLeod RS, Kunz JN, Hitchcock Y, Kokeny KE, Lloyd S, Ranjan (2025). Radiation induces diffuse extracellular remodeling of healthy myocardium in a dose- and time-dependent manner without a dense ablative effect. Heart rhythm, (Read full publication)
    87. Urias E, Lee J, Weil CR, Roach E, Lloyd S, Hashibe M, Facciabene A, Maity A, Tao (2025). Combined immune checkpoint inhibitors and ablative radiotherapy in metastatic cancers: a meta-analysis of prospective clinical trials. BMJ oncology, 4(1), e000732. (Read full publication)
    88. Chang Esther CP, Huang D, Lloyd S, Henry NL, O'Neil B, Hashibe (2025). Risks of adverse health outcomes among older rural prostate cancer survivors in the SEER-Medicare data. The Journal of rural health, 41(2), e70029. (Read full publication)
    89. Anker CJ, Arshad J, Cellini F, Dehal A, Dolan J, Gillett SR, Haddock MG, Haustermans K, Hong TS, Howell KJ, Jabbour SK, Kitano M, Lin C, Lloyd S, Peterson J, Roeder F, Smith GL, Stewart J, Tchelebi LT, Bradfield L, Willett C (2025). Radiation Therapy for Gastric Cancer: An ASTRO Clinical Practice Guideline. Practical radiation oncology, (Read full publication)

    Review

    1. Dinh TT, Mitin T, Bagshaw HP, Hoffman KE, Hwang C, Jeffrey Karnes R, Kishan AU, Liauw SL, Lloyd S, Potters L, Showalter TN, Taira AV, Vapiwala N, Zaorsky NG, D'Amico AV, Nguyen PL, Davis B (2021). Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. International journal of radiation oncology, biology, physics, 109(4), 953-963. (Read full publication)
    2. Torgeson A, Tao R, Garrido-Laguna I, Willen B, Dursteler A, Lloyd (2018). Large database utilization in health outcomes research in pancreatic cancer: an update. Journal of gastrointestinal oncology, 9(6), 996-1004. (Read full publication)
    3. Zhao P, Jin R, Zhao B, Han L, Chen W, Hao N, Cui Y, Madan A, Awosika J, Lloyd S, Zhang (2024). The efficacy-associated biomarkers for immune checkpoint inhibitors in gastrointestinal cancer: a literature review. Journal of gastrointestinal oncology, 15(1), 514-528. (Read full publication)
    4. Valle LF, Jiang T, Rosenbloom A, Zaorsky NG, Hwang C, Solanki A, Dickstein D, Mitin T, Schroeder T, Potters L, Lloyd S, Showalter T, Bagshaw HP, Jeffrey Karnes R, Hoffman KE, Nguyen PL, Kishan A (2024). American Radium Society Appropriate Use Criteria for the Workup and Treatment of Local Intraprostatic Recurrence of Prostate Cancer Following Definitive Radiotherapy. European urology oncology, (Read full publication)

    Conference Proceedings

    1. Gan M, Boothe D, Neklason DW, Samadder NJ, Frandsen J, Keener MB, Lloyd (2016). Outcomes and Complications of Radiation Therapy in Patients with Familial Adenomatous Polyposis.

    Editorial

    1. Lloyd (2018). Pancreas cancer, careful improvements and human connections. Journal of gastrointestinal oncology, 9(6), 979-981. (Read full publication)

    Other

    1. Ajani JA, D'Amico TA, Bentrem DJ, Corvera CU, Das P, Enzinger PC, Enzler T, Gerdes H, Gibson MK, Grierson P, Gupta G, Hofstetter WL, Ilson DH, Jalal S, Kim S, Kleinberg LR, Klempner S, Lacy J, Lee B, Licciardi F, Lloyd S, Ly QP, Matsukuma K, McNamara M, Merkow RP, Miller AM, Mukherjee S, Mulcahy MF, Perry KA, Pimiento JM, Reddi DM, Reznik S, Roses RE, Strong VE, Su S, Uboha N, Wainberg ZA, Willett CG, Woo Y, Yoon HH, McMillian NR, Stein (2025). Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. Journal of the National Comprehensive Cancer Network, 23(5), 169-191. (Read full publication)